PerkinElmer, Inc. (NYSE:PKI) insider Frank Anders Wilson sold 103,656 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $73.94, for a total transaction of $7,664,324.64. Following the completion of the sale, the insider now owns 93,624 shares in the company, valued at $6,922,558.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Frank Anders Wilson also recently made the following trade(s):
- On Thursday, December 7th, Frank Anders Wilson sold 37,535 shares of PerkinElmer stock. The shares were sold at an average price of $70.14, for a total transaction of $2,632,704.90.
Shares of PerkinElmer, Inc. (NYSE:PKI) traded down $1.05 on Wednesday, reaching $77.09. The company’s stock had a trading volume of 447,364 shares, compared to its average volume of 715,632. The stock has a market capitalization of $8,520.00, a price-to-earnings ratio of 32.39, a P/E/G ratio of 1.82 and a beta of 0.79. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.89 and a current ratio of 1.26. PerkinElmer, Inc. has a 1-year low of $55.41 and a 1-year high of $84.49.
PerkinElmer (NYSE:PKI) last announced its earnings results on Thursday, January 25th. The medical research company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.03. The company had revenue of $641.63 million during the quarter, compared to the consensus estimate of $619.14 million. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.83 earnings per share. equities research analysts anticipate that PerkinElmer, Inc. will post 3.52 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, May 10th. Stockholders of record on Friday, April 13th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.36%. PerkinElmer’s dividend payout ratio is currently 11.76%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. grew its stake in shares of PerkinElmer by 17.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 5,016 shares of the medical research company’s stock worth $367,000 after acquiring an additional 729 shares during the last quarter. Comerica Bank boosted its position in shares of PerkinElmer by 3.0% during the fourth quarter. Comerica Bank now owns 26,881 shares of the medical research company’s stock valued at $2,189,000 after buying an additional 772 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of PerkinElmer by 53.8% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,228 shares of the medical research company’s stock valued at $170,000 after buying an additional 779 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of PerkinElmer by 9.6% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,963 shares of the medical research company’s stock valued at $618,000 after buying an additional 788 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its position in shares of PerkinElmer by 2.8% during the third quarter. Nationwide Fund Advisors now owns 31,430 shares of the medical research company’s stock valued at $2,168,000 after buying an additional 851 shares during the last quarter. 91.94% of the stock is currently owned by hedge funds and other institutional investors.
PKI has been the topic of several analyst reports. Bank of America raised shares of PerkinElmer from an “underperform” rating to a “neutral” rating and set a $78.00 price target on the stock in a research report on Tuesday, December 19th. Evercore ISI assumed coverage on shares of PerkinElmer in a research note on Wednesday, January 3rd. They issued an “in-line” rating and a $77.00 price target on the stock. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research note on Monday, January 8th. Cowen restated a “hold” rating and issued a $84.00 price target on shares of PerkinElmer in a research note on Friday, January 26th. Finally, ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $76.85.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.